H.R. 7085 · 118th Congress
BIOSECURE Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
GallagherSponsor10 cosponsors · 6 D, 4 R
D
Auchincloss
ND
R
Dunn
RK
D
Krishnamoorthi
SM
D
Moulton
DD
D
Davis
ES
R
Stefanik
BW
R
Wenstrup
JM
R
Moolenaar
JG
D
Gottheimer
AE
D
Eshoo4 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.
What it does: CRS summary · Introduced in House · Jan 25, 2024
BIOSECURE Act
This bill prohibits federal contracting with certain biotechnology providers connected to foreign adversaries, with exceptions.
Specifically, the bill prohibits executive agencies from (1) procuring or obtaining any biotechnology equipment or service produced or provided by a biotechnology company of concern, or (2) entering into a contract or extending or renewing a contract that uses such equipment or service or that will require the direct use of such equipment or services. Those agencies may not obligate or expend loan or grant funds for such purposes.
A biotechnology company of concern includes BGI, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of such entities, and any entity that
- is subject to the jurisdiction, direction, control, or operates on behalf of the government of a foreign adversary;
- is involved in the manufacturing, distribution, provision, or procurement of a biotechnology equipment or service; and
- poses a risk to U.S. national security based on specified activities.
Executive agencies may waive the prohibitions on a case-by-case basis under specified circumstances.
The Office of Management and Budget must develop and periodically update a list of the entities that constitute biotechnology companies of concern.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: BIOSECURE Act
Latest action (Jan 25, 2024): Referred to the House Committee on Oversight and Accountability.
Policy area: Government Operations and Politics · Origin: House · Introduced: Jan 25, 2024
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.